Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway and associated pro-inflammatory cytokines (TNF, IL-6, IL-1β) (NF-κB/TNF/IL-6/IL-1β axis)

The NF-κB pathway and its downstream pro-inflammatory cytokines, including Tumor Necrosis Factor (TNF), Interleukin-6 (IL-6), and Interleukin-1 beta (IL-1β), constitute a central axis in the regulation of the innate and adaptive immune responses (StatPearls, 2023). NF-κB is a family of inducible transcription factors that, upon activation by various stimuli such as pathogens or stress, translocate to the nucleus to promote the expression of genes involved in inflammation and cell survival (Nature Reviews Immunology, 2017). TNF, IL-6, and IL-1β are key effector cytokines produced following NF-κB activation; they orchestrate systemic inflammation, fever, and the acute-phase response (PubMed, 2021). Dysregulation of this axis is a hallmark of numerous chronic inflammatory and autoimmune diseases, including rheumatoid arthritis and inflammatory bowel disease, as well as acute conditions like cytokine release syndrome (NIH, 2022). Therapeutic strategies targeting this pathway range from direct cytokine neutralization using monoclonal antibodies to the inhibition of intracellular signaling components, though such interventions carry risks of significant immunosuppression (PubChem, 2023). This multi-component target represents a critical node in inflammatory signaling where multiple therapeutic modalities converge to modulate immune-mediated pathology.

Other names

NF-kappaB signaling axisPro-inflammatory cytokine cascadeTNF-IL6-IL1B axisNF-κB-mediated inflammatory pathway

Therapeutic agents target this axis through several mechanisms: monoclonal antibodies (e.g., adalimumab, tocilizumab) and decoy receptors (e.g., etanercept) neutralize specific cytokines or block their receptors to prevent downstream signaling; proteasome inhibitors (e.g., bortezomib) prevent the degradation of IκB, thereby sequestering NF-κB in the cytoplasm; and corticosteroids (e.g., dexamethasone) broadly inhibit NF-κB transcriptional activity (PubMed, 2020; StatPearls, 2023).